Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir twice-daily versus every-8-hours dosing with peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 chronic hepatitis C
2010-021628-84Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of telaprevir in hepatitis C virus infection (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained virologic response at 12 weeks after planned end of treatment. Started Sep 2010; status: completed.
02
Drugs
telaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2010-021628-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021628-84.